Your AI-Trained Oncology Knowledge Connection!
A panelist discusses how patient-reported outcomes have transformed their ability to deliver more personalized care approaches for patients with polycythemia vera (PV) by providing critical insights into symptom burden, quality-of-life impacts, and treatment effectiveness that might otherwise go unrecognized through standard clinical assessments alone.
The panelist discusses how the patient underwent transarterial chemoembolization (TACE) 3 times with an initial partial response. However, at the end of the 6-month treatment period, the patient had disease progression. The panelist advises that the best treatment option for the patient would be systemic therapy.
A panelist discusses how advances in JAK2 V617F and other molecular monitoring have enhanced their ability to assess polycythemia vera (PV) disease progression and guide initial treatment decisions by providing quantifiable markers for tracking mutation burden, treatment response, and risk stratification that complement traditional clinical parameters.
An expert discusses how blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy derived from plasmacytoid dendritic cell precursors, presenting with skin lesions, lymphadenopathy, and bone marrow involvement. For a man aged 62 years, key concerns include rapid progression, immunophenotypic complexity, and potential misdiagnosis. Diagnostic challenges arise from its rarity and overlapping features with other hematologic disorders. Improved outcomes require multidisciplinary teams, standardized testing protocols, and specialized referral centers.
An expert discusses the patient case of a man aged 62 years who is newly diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The patient initially presented to the dermatologist with a progressive and persistent rash notable for bumps and nodules. The nodules presented a violet-like color, beginning on his forehead and spreading to the rest of his body.
An expert discusses what stands out most about this patient’s molecular profile and how these insights enhance the diagnostic approach in myeloproliferative neoplasms (MPNs).
An expert discusses the case of a 68-year-old woman diagnosed with primary myelofibrosis.
Panelists discuss how detailed analyses from KarMMa-3 reveal key insights about ide-cel’s performance across patient subgroups, timing of responses, durability of remissions, and management of adverse effects in relapsed/refractory multiple myeloma (RRMM).
Panelists discuss how the KarMMa-3 trial demonstrated superior efficacy of idecabtagene vicleucel (ide-cel) chimeric antigen receptor T-cell therapy compared to standard treatment regimens in patients with heavily pretreated, triple-class–exposed relapsed/refractory multiple myeloma (RRMM).
The panelists discuss how the RATIONALE-306 trial demonstrated efficacy outcomes through its design, measuring both progression-free survival and overall survival as key end points.
A panelist discusses how treatment sequencing decisions in RCC span multiple lines of therapy, incorporating various options like tivozanib, lenvatinib-everolimus combinations, and belzutifan, with careful consideration given to optimal dosing strategies, expected duration of therapy, anticipated response patterns, and the specific timing of each agent in the treatment journey, particularly in the post-ICI setting.
An expert discusses the safety findings from the PEACE-3 study, highlighting the adverse events associated with the combination of enzalutamide and radium-223 in ARPI-naïve metastatic castration-resistant prostate cancer.
An expert discusses the key efficacy findings from the PEACE-3 study, including results on radiographic progression-free survival (rPFS) and overall survival (OS), and offers insights on how to interpret and apply these results in clinical practice.
A panelist discusses how second-line therapy selection in metastatic RCC requires careful consideration of multiple factors including prior treatment response, individual patient characteristics, specific drug properties (such as mechanism of action and pharmacokinetics), strength of clinical evidence, and practical considerations like tolerability and quality of life, while acknowledging current evidence gaps and unmet needs in the post-ICI treatment landscape.
Panelists discuss the emerging potential of KRAS inhibition in metastatic cancer treatment, exploring novel therapies and their promise for patients with KRAS-mutated tumors.
Panelists discuss individualized treatment selection for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on targeted therapies and personalized approaches to improve patient outcomes.
An expert discusses how efficacy and safety data from trials such as METEOR, TIVO-3, TiNivo-2, and LITESPARK-005 guide third line (3L) renal cell carcinoma (RCC) treatment. Differences in trial populations, evolving long-term trends, and prior immune checkpoint inhibitor (ICI) use impact applicability. CONTACT-03 and TiNivo-2 provide key insights, and real-world data and patient-reported outcomes refine clinical decision-making. Community oncologists should critically assess study limitations and evolving evidence when selecting therapy.
An expert discusses how first-line (1L) systemic therapy for unresectable hepatocellular carcinoma (uHCC) has evolved significantly from sorafenib monotherapy to include combination approaches such as atezolizumab plus bevacizumab, which demonstrated superior outcomes in the IMbrave150 trial. Key challenges include underlying liver dysfunction, heterogeneous tumor biology, and managing adverse events while preserving quality of life. Treatment goals focus on extending survival while maintaining liver function and performance status. The shift toward immunotherapy-based combinations has improved outcomes, though patient selection and sequencing strategies remain important considerations in optimizing first-line treatment decisions in clinical practice.
A panelist discusses how, based on the NCCN guidelines for kidney cancer, third-line treatment options for this patient include cabozantinib, lenvatinib plus everolimus, tivozanib, and everolimus monotherapy. Clinical trials and best supportive care remain important considerations at this stage.
An expert discusses the patient case of a 57-year-old woman diagnosed with advanced unresectable hepatocellular carcinoma. The patient presented with abdominal pain, fatigue, and loss of appetite. She also has a history of Crohn disease, which is being controlled with infliximab. The patient also has a history of variceal bleeding and has been treated with antiviral therapy for chronic hepatitis B virus infection.
A panelist discusses how a patient’s initial presentation and molecular profile guide personalized treatment approaches for polycythemia vera (PV), weighing factors such as symptom burden, risk stratification, and genetic markers to optimize therapeutic outcomes.
A panelist discusses how a 67-year-old male smoker presented with frequent headache and dizziness but had an otherwise unremarkable medical history with no splenomegaly.
Panelists discuss how recent clinical trial data and emerging therapeutic options are reshaping the treatment paradigm for myelofibrosis, requiring thoughtful integration of new evidence into current clinical practice guidelines.
Panelists discuss how recent updates in progression free survival data complement secondary endpoints of overall survival, overall response rates, and duration of response to provide a comprehensive picture of treatment efficacy.
Panelists discuss how the latest progression-free survival, overall survival, and overall response rate data presented at ASCO 2025 demonstrate significant advancements in treatment efficacy across multiple tumor types.
Panelists discuss how incorporating both neoadjuvant and adjuvant treatment approaches into clinical trial designs has shown promising improvements in event-free survival outcomes across multiple cancer types.
Panelists discuss how recent clinical data presented at ASCO 2025 showed varying results across primary endpoints including overall survival, progression-free survival, efficacy measures, and safety profiles, with key opinion leaders highlighting implications for current treatment paradigms.
Panelists discuss how to select optimal therapy for a 66-year-old patient with early relapse following autologous stem cell transplantation (ASCT), considering factors such as prior treatment exposure, duration of response, and emerging therapeutic options including cellular therapies.
Panelists discuss how to identify, monitor, and manage delayed toxicities following ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor (CAR) T therapy, including prolonged cytopenias, infections, and neurotoxicity, to optimize long-term patient outcomes and safety.
A panelist discusses how patient-reported outcomes and real-world evidence contribute valuable insights into the practical impact of these treatments, complementing traditional efficacy measures and helping inform clinical decision-making in actual practice settings.